SAN DIEGO – Given the steep decline in third quarter biotech fundraising – down 48 percent from the same period last year – it's no surprise that companies are looking for alternatives. And at the recent Foley & Lardner Life Sciences conference in San Diego, a panel debated the merits of considering mergers and acquisitions as a financing strategy rather than an exit strategy.